Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data.

Clinical pharmacokinetics - 1 Nov 2021

Frederiksen Trine, Smith Robert L, Wollmann Birgit M, Areberg Johan, Molden Espen

Abstract excerpt

INTRODUCTION: Vortioxetine is an antidepressant primarily metabolized by the polymorphic enzyme cytochrome P450 (CYP) 2D6. A population pharmacokinetic (popPK) model of vortioxetine and its CYP2D6-dependent metabolite was recently published. OBJECTIVE: The aim of the current study was to assess the predictive performance of the popPK model using vortioxetine concentration measurements from a clinical setting....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Drug Monitoring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Source

Open in PubMed Open full text

Identifiers

PMID: 34121163
DOI: 10.1007/s40262-021-01029-7
PMCID: PMC8585800

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data.PMID 34121163Read ↗

Using population pharmacokinetic analyses of drugs metabolized by CYP2D6 to study the genotype-phenotype translation.Semantic proximity Read ↗

Association between CYP2D6 genotype and vortioxetine exposure and therapeutic failure - a retrospective, cohort studySemantic proximity Read ↗

Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles Through Population Pharmacokinetic Analysis of Vortioxetine.Semantic proximity Read ↗

PBPK modeling of the antidepressant doxepin incorporating CYP2D6 genotype for precision pharmacotherapy.Semantic proximity Read ↗

Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype-Guided Dosing of Tamoxifen.Semantic proximity Read ↗

Physiologically Based Pharmacokinetic Modeling to Unravel the Drug-gene Interactions of Venlafaxine: Based on Activity Score-dependent Metabolism by CYP2D6 and CYP2C19 Polymorphisms.Semantic proximity Read ↗

Cytochrome P450 2D6 genotype-phenotype characterization through population pharmacokinetic modeling of tedatioxetine.Semantic proximity Read ↗

Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes.Semantic proximity Read ↗

PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine.Semantic proximity Read ↗

CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression.Semantic proximity Read ↗

Association Between CYP2D6 Metabolizer Status and Vortioxetine Exposure and Treatment Switching: A Retrospective, Naturalistic Cohort Study Using Therapeutic Drug Monitoring Data From 640 Patients.Semantic proximity Read ↗

Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.